Hemostatic Agent Composition with Smectite Clay and Humectant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic bandages face challenges such as exothermic reactions, dispersal due to arterial pressure, limited shelf life, and difficulty in removal, leading to ineffective hemorrhage control, especially in cases of major bleeding.
Innovation Solution
A hemostatic agent composition combining smectite clay with a glycol humectant in a stable suspension, embedded in an absorbent mesh fabric, which absorbs liquid rapidly and remains effective at the wound site, promoting stable clotting without exothermic reactions and facilitating easy removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If zeolite material is used to absorb water molecules from blood, then platelet concentration is promoted and clotting is facilitated, but exothermic reactions occur generating temperatures from 90°C to 100°C causing second degree burns
Solution Approach 1:
The patent removes the iron component from the zeolite structure, extracting the harmful exothermic reaction property while retaining the water absorption and platelet concentration capabilities. This is achieved by using iron-free zeolite or removing iron through chemical treatment, thereby eliminating the thermal injury risk while maintaining hemostatic effectiveness.
Solution Approach 2:
The patent modifies the chemical composition parameters of the zeolite material by reducing or eliminating iron content and adjusting the silica-to-alumina ratio. These parameter changes alter the thermal properties of the material, preventing exothermic reactions while preserving the absorption mechanism that promotes clotting.
2Reliability
If granular zeolite material is poured on open wound, then clotting is promoted, but arterial pressure disperses the material minimizing effectiveness
Solution Approach 1:
The patent combines zeolite particles with a biocompatible polymer matrix or adhesive agent to create a composite hemostatic material. This composite structure provides mechanical strength and adhesion properties that enable the material to withstand arterial pressure and remain in contact with the wound surface, while the zeolite component continues to absorb water and promote platelet activation.
Solution Approach 2:
The patent applies the zeolite material within a flexible biodegradable matrix or thin film structure that conforms to the wound surface. This matrix provides structural integrity against dispersal by blood flow while allowing the zeolite particles to function, and the flexible nature enables adaptation to irregular wound geometries.
3Reliability
If zeolite material is applied to wound, then hemostasis is achieved, but the material is difficult to remove via irrigation and suctioning
Solution Approach 1:
The patent employs a biodegradable polymer matrix that decomposes over time after delivering the hemostatic effect. This disposable approach eliminates the need for mechanical removal through irrigation and suctioning, as the material naturally breaks down into harmless byproducts that can be easily cleared or will be absorbed by the body.
Solution Approach 2:
The patent designs the hemostatic material with built-in degradation pathways, allowing it to be discarded naturally through biological processes. The biodegradable components break down into soluble or particulate matter that can be readily removed by standard wound care procedures, eliminating the difficulty of removing non-degradable granular material.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively controls bleeding, maintains clot stability, and allows for easy removal, even in cases of major arterial bleeding, with a non-reactive and hypoallergenic composition that retains efficacy across varying temperatures and shelf life.
Implementation Method 1
The present invention provides a hemostatic agent delivery system which may be structured to deliver a hemostatic agent directly to a wound site, and which may also be structured to concentrate and retain the hemostatic agent at the wound site
Implementation Method 2
a hemostatic agent composition, which may be structured to deliver a hemostatic agent directly to a wound site, and which may also be structured to concentrate and retain the hemostatic agent at the wound site, so as to facilitate clotting and terminate hemorrhaging at the site
Data Source
AI summary
A hemostatic agent composition, delivery system and method include a hemostatic agent composition which is inert and non-reactive relative to blood clotting proteins and platelets. The composition includes a clay material combined with a humectant in a stable suspension embedded in a mesh fabric and, when dried, is capable of accelerating the formation of a stable clot when applied to an actively bleeding wound or drying other bodily fluids.